

6-K Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 6-K Â
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF
1934 For the month of February, 2025 Commission File No. 001-39621 Â OPTHEA LIMITED (Translation of
Registrantâ€™s name into English) Â Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of
Registrantâ€™s principal executive office) Â Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F. Form 20-F â˜ Form 40-F â˜ Â Â Â Â EXHIBIT INDEX Â Exhibit
Â Description 99.1 Â Opthea to Present at Oppenheimer Healthcare Conference Â Â Â Â Â Â Â SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereto duly authorized. Â Â OPTHEA LIMITED Â (Registrant) Â Â Â Â By:
/s/ Frederic Guerard Â Name: Frederic Guerard Â Title: Chief Executive Officer Â Date: 02/07/2025 Â EX-99.1 Exhibit
99.1 Â ASX, Nasdaq and Media Release Â February 7, 2025 Â Opthea to Present at Oppenheimer Healthcare
Conference Melbourne, Australia, and Princeton, NJ, US, February 7, 2025 -- Opthea Limited (ASX/NASDAQ:OPT,
â€œOptheaâ€, the â€œCompanyâ€), a clinical-stage biopharmaceutical company developing novel therapies to treat
highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today
announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimerâ€™s 35th Annual
Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimerâ€™s 35th
Annual Healthcare Life Sciences Conference Date: February 11-12, 2025 Presentation: Tuesday, February 11, 2025,
10:00 AM ET Webcast Link: <https://wsw.com/webcast/oppenheimer39/opt/2588856> The webcast will also be accessible
on the â€œEvents & Presentationsâ€ section of the Companyâ€™s website at <http://ir.opthea.com/>. Â Â About Opthea
Â Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs
in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration
(wet AMD) and diabetic macular edema (DME). Optheaâ€™s lead product candidate, sozinibcept, is being evaluated
in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in
combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains
compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow
us on X and LinkedIn. Â Authorized for release to ASX by Frederic Guerard, PharmD, CEO Â Â Â Â Â Â Â Â Â Â Â
Investor Inquiries Join our email database to receive program updates: PJ KelleherLifeSci Advisors LLC Email:
pkelleher@lifesciadvisors.com Phone: 617-430 7579 Â Media Inquiries Silvana Guerci-Lena NorthStream Global
Partners Email: silvana@nsgpllc.com Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web:
www.opthea.com Â Â Â Â Source: Opthea Limited Â Â